Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

J&J's $21B Synthes Bet Could End With $20B Sale to Apollo Global

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at mddionline.com →

◆ Verified

Fusion42 · 15 September 2026 · Fusion42 review

Johnson & Johnson is considering selling its Synthes orthopedic business to Apollo Global for nearly $20 billion after a prior $21 billion acquisition, signaling a major shift in medtech ownership.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Apollo Global’s approach opens a door for medtech firms to rethink ownership and capital structure as private equity re-enters orthopedic device ownership. You need to prepare for a more active market for medtech divestitures and partnerships.

◆ Coverage

2 sources · 14 Sep 2026

◆ Related on Wire

◆ Topics

Medtechmedtechprivate-equitym-aorthopediccorporate-strategy